PDCD1 and melanoma: Another limitation lies in the fact that most of the patients (84%) described in the present series were treated with ipilimumab monotherapy, which is no longer the standard of care in melanoma; instead, melanoma treatment nowadays involves anti-PD-1 monoclonal antibodies, applied both as single agents and in combination with ipilimumab.